Literature DB >> 3357926

R(-)-2,5-dimethoxy-4-77 bromoamphetamine [77Br-R(-)DOB]: a novel radioligand which labels a 5-HT binding site subtype.

S S Wang1, C A Mathis, S J Peroutka.   

Abstract

R(-)-2,5-Dimethoxy-4-77Br-amphetamine [77Br-R(-)DOB], a radioligand of high specific activity (1500 +/- 200 Ci/mmol), was used to label membrane-associated recognition sites in rat brain. 77Br-R(-)DOB sites were of high affinity (KD = 0.19 nM) but low density (Bmax = 0.32 pmol/g tissue) in rat brain preparations. Competition experiments show that both 5-hydroxytryptamine (5-HT) and 5-HT2 antagonists display nanomolar potency for these sites. We conclude that 77Br-R(-)DOB labels 5-HT recognition sites in rat brain which do not fit into current classifications of 5-HT binding subtypes. This finding may be of aid in deciphering the mechanism of action of hallucinogens in man.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3357926     DOI: 10.1007/bf00174703

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  3 in total

1.  Ligand dissociation constants from competition binding assays: errors associated with ligand depletion.

Authors:  A Goldstein; R W Barrett
Journal:  Mol Pharmacol       Date:  1987-06       Impact factor: 4.436

2.  [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors.

Authors:  M Titeler; K Herrick; R A Lyon; J D McKenney; R A Glennon
Journal:  Eur J Pharmacol       Date:  1985-10-29       Impact factor: 4.432

3.  3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors.

Authors:  R A Lyon; K H Davis; M Titeler
Journal:  Mol Pharmacol       Date:  1987-02       Impact factor: 4.436

  3 in total
  1 in total

1.  Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex.

Authors:  P A Pierce; S J Peroutka
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.